Home > Education Hub > We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

News

Category:

M&A Pharma

Published on:

December 20, 2020

Alira Health is pleased to announce its role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Merieux Equity Partners is a global asset manager specialized in the healthcare and nutrition sectors. Cell-Easy is a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies for preclinical and clinical studies. This fund raising aims at accelerating the company’s growth in France and internationally, by expanding the Cell-Easy Management Team and strengthening the company’s commercial presence in key regions.

To read the press release on BusinessWire, click here.

For more information, contact Joris Pezzini.

For more information about Alira Health Transaction Advisory services

Click here

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

For more information about Alira Health Transaction Advisory services

Related news

Event: World Drug Safety Congress

Event: Meeting on the Mesa

What You Should Know Before Choosing a Healthcare Transaction Advisory Firm

Infographic: Prioritization Strategy of R&D Targets for Biotech Company

Alira Health Announces its Role as Strategic Advisor to Naxicap

Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes

Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev

Our locations around the globe